Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

ators on a submission to gain regulatory approval for Gleevec as adjuvant treatment for GIST."

Following the recommendation of a data monitoring committee, the study will be closed and patients in the study who are currently being treated with placebo may choose to receive one year of Gleevec.

In the study, patients were randomized to one of two treatment arms. Neither the patients nor physicians knew which treatment the patients were receiving. One patient group received Gleevec at a dose of 400 milligrams per day for one year, while the second group received placebo for one year. According to the study design, patients who developed a recurrence of their cancer while on a study therapy were unblinded to their treatment assignment. Those receiving placebo subsequently received Gleevec, while those already given Gleevec continued with this therapy but at a higher dose. Study results will be presented at a forthcoming scientific meeting.

Gastrointestinal stromal tumors (GIST) belong to a group of cancers known as soft tissue sarcomas that usually arise from the intestinal tract, with the most common site being the stomach followed by the small intestine. The incidence of GIST is estimated to be 4,500-6,000 new cases per year in the US (15-20 cases per million population), of which more than 90% are kit-positive.

Investigators in the NCI study reported that Gleevec therapy was well tolerated by most patients, with side effects similar to those observed in other clinical trials with Gleevec. These include nausea, diarrhea and swelling (edema). Information on more than 600 patients enrolled in the study was used in the analysis.

About Gleevec

Gleevec(R) (imatinib mesylate) is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). The effectiveness of Gleevec in GIST is based on objective response rate. There are no controlled trials demon
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
(Date:5/22/2015)... , May 22, 2015 According ... Market by Product (Consumables, Instruments, Services), by Test Type ... Chromatography, Flow Cytometry), by End Users - Global Forecast ... Market is expected to reach $736.85 Million by 2020 ... of 10.25%. Browse 71 market data ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
... research at SRI International, scientists evaluating new drug targets against ... that could rapidly eliminate infections and potentially shorten treatment time. ... B, found in bacteria that cause TB infections. ... A and gyrase B. Although gyrase A is often the ...
... 29, 2011   Acuo Technologies ® ... for intelligent medical image lifecycle management and data ... has selected the Universal Clinical Platform (UCP3) ... UCP3 will replace Fairview,s existing PACS archives while ...
Cached Medicine Technology:SRI Researchers Validate Preclinical Effectiveness of Tuberculosis Drug Target that Could Shorten Treatment Time 2Acuo Technologies Announces Vendor Neutral Archiving Contract with Fairview Health Services 2Acuo Technologies Announces Vendor Neutral Archiving Contract with Fairview Health Services 3
(Date:5/22/2015)... May 22, 2015 The world ... and capacity are intersecting to create new opportunities ... the opening speaker at WesternU's 34th annual Commencement ... Gov. Gavin Newsom, a former San Francisco mayor ... speaker at the graduation ceremony for WesternU's colleges ...
(Date:5/22/2015)... Liverpool, OH (PRWEB) May 22, 2015 ... announced that Kyle Johnson, the health system’s Chief Financial ... other interests. Johnson has served as the company CFO ... Wesley West will be joining the health system as ... on an interim basis, while the Board of Trustees ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
(Date:5/22/2015)... 2015 Carnegie Science Center ... a new partnership to develop BodyTech, a dynamic, three-pronged ... initiative includes a new exhibit at the Science Center ... and a new traveling science show, Anatomy Adventure, which ... , Designed to explore a wide range of ...
(Date:5/22/2015)... Power Systems is proud to announce the ... season. Drobeck is in his second year of racing in ... the Missoula Fire Department in Missoula, MT. He entered the ... During his career, he has had 15 1st Place finishes. ... 10 finishes in all seven of his 2014 races, including ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... Scientists at the ,University of North Carolina at Chapel ... plays a central role in the formation of new blood ... new blood vessel formation, or angiogenesis, is seriously impaired without ... 2011 in the journal Blood , was led by ...
... prevention trial that has been evaluating two antiretroviral (ARV)-based approaches ... daily use of one of two different ARV tablets or ... The decision to discontinue use of the gel, which contains ... study data concluded tenofovir gel was not effective in preventing ...
... -- Patients hospitalized for autoimmune disorders, like rheumatoid arthritis ... life-threatening pulmonary embolism, a clot in a main artery of ... 25 in The Lancet , researchers warned that steps ... to the hospital for autoimmune diseases. , , In conducting ...
... CHICAGO By combining conventional medical imaging with some ... blockbusters, researchers are offering new hope to victims of ... human face transplantation, led by Darren M. Smith, M.D., ... Center (UPMC), were presented today at the annual meeting ...
... News) -- Racism is similar to trauma in how ... the United States, a new analysis finds. An ... 18,000 black adults concluded that there are common responses ... that is expressed as physical pain), interpersonal sensitivity and ...
... should be able to choose where they give birth, concludes ... first-time mums who opt for a home birth are at ... low in all birth settings. The researchers say their ... pregnancies a choice of birth setting" and will enable women ...
Cached Medicine News:Health News:Cell molecule identified as central player in the formation of new blood vessels 2Health News:Cell molecule identified as central player in the formation of new blood vessels 3Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 2Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 3Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 4Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 5Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 6Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 7Health News:Autoimmune Woes May Raise Risk for Lung Clots 2Health News:Integrated 3-D imaging facilitates human face transplantation 2Health News:Integrated 3-D imaging facilitates human face transplantation 3Health News:Pregnant women at low risk of complications can safely be offered a choice of where to give birth 2
Stainless steel bone clamp....
Lewin Bone Forceps, serrated and slightly curved. To hold, stabilize, rotate, reduce and,compress bone....
Straight double action bone cutting rongeur....
Beuse Zygomatic Arch Awl with slightly curved tip....
Medicine Products: